Intercept Pharmaceuticals Inc (ICPT) : Linden Advisors Lp added new position in Intercept Pharmaceuticals Inc during the most recent quarter end. The investment management firm now holds 9,316 shares of Intercept Pharmaceuticals Inc which is valued at $1,518,415 , the company said in a statement filed on Aug 15, 2016 with the SEC.Intercept Pharmaceuticals Inc makes up approximately 0.75% of Linden Advisors Lp’s portfolio.
Other Hedge Funds, Including , Clearbridge Investments boosted its stake in ICPT in the latest quarter, The investment management firm added 272 additional shares and now holds a total of 523 shares of Intercept Pharmaceuticals Inc which is valued at $85,244. Jefferies Group sold out all of its stake in ICPT during the most recent quarter. The investment firm sold 2,523 shares of ICPT which is valued $411,224. Bessemer Group Inc sold out all of its stake in ICPT during the most recent quarter. The investment firm sold 65 shares of ICPT which is valued $10,594.South Dakota Investment Council reduced its stake in ICPT by selling 3,600 shares or 7.5% in the most recent quarter. The Hedge Fund company now holds 44,400 shares of ICPT which is valued at $7,236,756. Intercept Pharmaceuticals Inc makes up approx 0.15% of South Dakota Investment Council’s portfolio.
Intercept Pharmaceuticals Inc closed down -1.49 points or -1.00% at $146.82 with 2,67,496 shares getting traded on Thursday. Post opening the session at $149, the shares hit an intraday low of $146 and an intraday high of $149.99 and the price fluctuated in this range throughout the day.Shares ended Thursday session in Red.
On the company’s financial health, Intercept Pharmaceuticals Inc reported $-3.14 EPS for the quarter, beating the analyst consensus estimate by $ 0.53 according to the earnings call on Aug 4, 2016. Analyst had a consensus of $-3.67. The company had revenue of $5.52 million for the quarter, compared to analysts expectations of $.87 million. The company’s revenue was up 1140.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-1.99 EPS.
Many Wall Street Analysts have commented on Intercept Pharmaceuticals Inc. Shares were Downgraded by Laidlaw on Aug 5, 2016 to ” Sell” and Lowered the Price Target to $ 105 from a previous price target of $345 .Cantor Fitzgerald Initiated Intercept Pharmaceuticals Inc on Jul 6, 2016 to “Sell”, Price Target of the shares are set at $58.Shares were Reiterated by Wedbush on Jun 1, 2016 to “Outperform” and Lowered the Price Target to $ 239 from a previous price target of $423 .
Intercept Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat chronic liver diseases utilizing its bile acid chemistry. The Companys product candidate obeticholic acid (OCA) is a bile acid analog a chemical substance that has a structure based on a naturally occurring human bile acid that selectively binds to and activates the farnesoid X receptor (FXR). The Company is also developing other products INT-767 and INT-777 for the treatment of fibrosis and type 2 diabetes. OCA has been tested in five placebo-controlled clinical trials including a completed Phase III clinical trial in patients with primary biliary cirrhosis (PBC) and two Phase II clinical trials in patients with nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH). OCA met the primary efficacy endpoint in each of these trials with statistical significance.